SEARCHNARRATIVE_REVIEWnutrition, endocrinology

narrative_review·nutrition, endocrinology, gastroenterology, clinical nutrition·PMC10589153

Endocrine, genetic, and microbiome nexus of obesity and potential role of postbiotics: a narrative review

Eating and Weight Disorders · 7 authors, 3 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

It discusses the potential of postbiotics, such as short-chain fatty acids, as anti-obesity agents by regulating metabolic hormones and appetite.

Full summary

294 CHARS

It discusses how genetic mutations (e.g., in leptin, leptin receptor, MC4R) can lead to monogenic obesity and metabolic consequences. The paper synthesizes evidence from the literature to suggest postbiotics as potential anti-obesity agents that interact with genetics, hormones, and nutrition.

STUDY TYPE

narrative_review

SPECIALTY

nutrition

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10589153

Endocrine, genetic, and microbiome nexus of obesity and potential role of postbiotics: a narrative review

Eating and Weight Disorders

READ THE FULL PAPER

ABSTRACT

Abstract Obesity is a public health crisis, presenting a huge burden on health care and the economic system in both developed and developing countries. According to the WHO’s latest report on obesity, 39% of adults of age 18 and above are obese, with an increase of 18% compared to the last few decades. Metabolic energy imbalance due to contemporary lifestyle, changes in gut microbiota, hormonal imbalance, inherent genetics, and epigenetics is a major contributory factor to this crisis. Multiple studies have shown that probiotics and their metabolites (postbiotics) supplementation have an effect on obesity-related effects in vitro, in vivo, and in human clinical investigations. Postbiotics such as the SCFAs suppress obesity by regulating metabolic hormones such as GLP-1, and PPY thus reducing feed intake and suppressing appetite. Furthermore, muramyl di-peptides, bacteriocins, and LPS have been tested against obesity and yielded promising results in both human and mice studies. These insights provide an overview of targetable pharmacological sites and explore new opportunities for the safer use of postbiotics against obesity in the future. Keywords: Obesity, Energy metabolism, Gut microbiome, Postbiotics, SCFAs, Muramyl di-peptides, Bacteriocins, LPS

CITATION EXPORT

Weiming Wu, Zhengfang Chen, Jiani Han et al.. Endocrine, genetic, and microbiome nexus of obesity and potential role of postbiotics: a narrative review. Eating and Weight Disorders. (2023). https://doi.org/10.1007/s40519-023-01593-w

AUTHORS

7 · 3 CENTRES

Weiming Wu, Zhengfang Chen, Jiani Han, Lingling Qian, Wanqiu Wang, Jiacai Lei, Huaguan Wang

1Department of Endocrinology, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu, 215500 Jiangsu People’s Republic of China
2Department of Endocrinology, Changshu First People’s Hospital, Changshu, 215501 Jiangsu People’s Republic of China
3Department of Gastroenterology, Hangzhou Ninth People’s Hospital, Hangzhou, 310005 Zhejiang People’s Republic of China